HRSA solicits newborn-screening review

HRSA’s Maternal and Child Health Bureau has put a new federal procurement behind newborn-screening evidence review, opening a solicitation for a multiple-award contract that would support systematic reviews tied to newborn-screening systems. The notice, posted on SAM.gov, says the agency is seeking three to five contractors under an indefinite-delivery, indefinite-quantity, or IDIQ, vehicle. The stated aim is to secure specialized scientific methods and systematic clinical evidence-review capacity for newborn-screening work. That procurement lands weeks after HRSA said it was modernizing the national newborn-screening review process. In an Aug. 11 press release, the agency said the new framework would streamline evidence review for conditions considered for the Recommended Uniform Screening Panel, or RUSP, which guides state newborn-screening programs. ### What exactly did HRSA ask contractors to do? (sam.gov) The SAM.gov solicitation describes a “full and open competitive” process to establish a multiple-award IDIQ pool for newborn-screening systematic evidence review work. HRSA said the objective is to secure highly specialized scientific methodologies and systematic clinical evidence-review support, with the contract structured so the agency can issue task orders for specific assignments. (hrsa.gov) The notice indicates the procurement is being run by the Health Resources and Services Administration within the Department of Health and Human Services, through the Maternal and Child Health Bureau. The listed product-service code is for professional support services, and the solicitation uses NAICS code 541690, “Other Scientific and Technical Consulting Services.” ### Why does a contract notice matter in newborn screening? (sam.gov) HRSA already funds and supports newborn-screening infrastructure across the country. The bureau says newborn screening is designed to find serious but treatable conditions early in a baby’s life so infants can get care, treatment or other help as soon as possible. An evidence-review contract matters because national newborn-screening decisions rely on formal reviews of benefits, harms, health impacts and implementation issues. (sam.gov) A prior HRSA-backed evidence review for mucopolysaccharidosis type II, for example, laid out key questions on screening, epidemiology, treatment and likely effects on state programs. (mchb.hrsa.gov) ### How does this fit with HRSA’s August overhaul of the review process? HRSA said on Aug. 11 that it was adopting a modernized framework for addressing newborn-screening topics, including evaluating conditions for possible inclusion in the RUSP. The agency said the framework would streamline evidence review and strengthen national recommendations. That makes the new solicitation look less like a standalone purchase and more like part of the machinery needed to run the revised process. (hrsa.gov) That is an inference from the timing and subject matter of the two HRSA actions, not a characterization the agency made in the solicitation itself. ### What is the Maternal and Child Health Bureau’s role here? MCHB says it works to strengthen public-health systems for mothers, infants, children and families, reaching about 59 million pregnant mothers, infants and children, including children with special health care needs. (hrsa.gov) Newborn screening sits squarely inside that mission because it is one of the earliest population-wide child-health interventions. HRSA’s newborn-screening program pages say all newborn babies in the United States are screened for rare but serious health conditions, and that timely follow-up is central because the conditions identified are treatable and require prompt action. (sam.gov) ### What should readers watch next? SAM.gov is the main place to watch for amendments, questions, closing dates and any later award notices tied to the solicitation. (mchb.hrsa.gov) The government’s contract-opportunities portal says procurement notices there include solicitations, amendments and award information for vendors doing business with federal agencies. Any eventual task-order awards under the IDIQ would show how quickly HRSA moves from setting up the contractor pool to commissioning specific newborn-screening evidence reviews. (newbornscreening.hrsa.gov) HRSA’s Aug. 11 modernization announcement and the SAM.gov opportunity are the clearest public markers so far of that next phase. (hrsa.gov) (sam.gov)